肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Lancet Oncol：Nintedanib+多西他赛二线治晚期NSCLC有效

2014-03-10 1 月 9 日 Lancet Oncol 在 线 发 表 医学论坛网

多西他赛非小细胞肺癌
关注

1月9日，Lancet Oncol在线发表Ⅲ期随机双盲对照研究LUME-Lung1的结果。该研究旨在评估多西他赛+nintedanib作为二线治疗非小细胞肺癌(NSCLC)的有效性和安全性。LUME-Lung1研究纳入了来自27个国家、211个中心的一线化疗后复发的ⅢB～Ⅳ期非小细胞肺癌(NSCLC)患者。从2008年12月23日到2011年2月9日之间,患者随机分为多西他赛联合Nintedani

1月9日，Lancet Oncol在线发表Ⅲ期随机双盲对照研究LUME-Lung1的结果。该研究旨在评估多西他赛+nintedanib作为二线治疗非小细胞肺癌(NSCLC)的有效性和安全性。

LUME-Lung1研究纳入了来自27个国家、211个中心的一线化疗后复发的ⅢB～Ⅳ期非小细胞肺癌(NSCLC)患者。

从2008年12月23日到2011年2月9日之间,患者随机分为多西他赛联合Nintedanib(655例)组和对照组(659例)。平均随访7.1个月后初次分析显示，与安慰剂对照，多西他赛联合nintedanib组的PFS显著延长(3.4个月对2.7个月，P=0.0019)。31.7个月后，肺腺癌患者接受多西他赛联合nintedanib组(322例)的OS显著优于对照组(336例)(12.6个月对10.3个月，P=0.0359)。两药联合组≥3级的不良事件更常见。

原始出处：

Reck M1, Kaiser R2, Mellemgaard A3, Douillard JY4, Orlov S5, Krzakowski M6, von Pawel J7, Gottfried M8, Bondarenko I9, Liao M10, Gann CN11, Barrueco J12, Gaschler-Markefski B13, Novello S14; LUME-Lung 1 Study Group.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702916, encodeId=d2cc1e029162c, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sat Mar 15 03:36:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864513, encodeId=bcc71864513d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 27 15:36:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827723, encodeId=5492182e72321, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 23 17:36:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416253, encodeId=307d141625374, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-15 aliceclz

    #TED#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1702916, encodeId=d2cc1e029162c, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sat Mar 15 03:36:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864513, encodeId=bcc71864513d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 27 15:36:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827723, encodeId=5492182e72321, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 23 17:36:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416253, encodeId=307d141625374, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-04-27 医者仁心

    #Oncol#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1702916, encodeId=d2cc1e029162c, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sat Mar 15 03:36:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864513, encodeId=bcc71864513d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 27 15:36:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827723, encodeId=5492182e72321, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 23 17:36:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416253, encodeId=307d141625374, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-10-23 howi

    #Lancet#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1702916, encodeId=d2cc1e029162c, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sat Mar 15 03:36:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864513, encodeId=bcc71864513d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 27 15:36:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827723, encodeId=5492182e72321, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 23 17:36:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416253, encodeId=307d141625374, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 xiongke010

    #Nintedanib#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1702916, encodeId=d2cc1e029162c, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sat Mar 15 03:36:00 CST 2014, time=2014-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864513, encodeId=bcc71864513d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Apr 27 15:36:00 CST 2014, time=2014-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827723, encodeId=5492182e72321, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Oct 23 17:36:00 CST 2014, time=2014-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361778, encodeId=1bb91361e78d2, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416253, encodeId=307d141625374, content=<a href='/topic/show?id=6cef59801ea' target=_blank style='color:#2F92EE;'>#晚期NSCLC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59801, encryptionId=6cef59801ea, topicName=晚期NSCLC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b093156350, createdName=经常头晕, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 经常头晕

    #晚期NSCLC#

    0

相关资讯

尼达尼布联合化疗可延长肺腺癌患者的生存期

LUME-Lung 1 III期临床试验结果显示，新型在研化合物、口服三联血管激酶抑制剂尼达尼布（BIBF1120）联合多西他赛可使非小细胞肺癌（NSCLC）腺癌患者的生存期相较安慰剂联合多西他赛治疗组患者延长2.3个月。 LUME-Lung 1 试验显示了二线治疗药物联合化疗相较于单用化疗在总生存上的益处。尼达尼布联合多西他赛治疗组的腺癌患者相较安慰剂联合多西他赛治疗组的腺癌患者，其总生存期获

肺腺癌患者多西他赛联合ganetespib治疗可延长患者总生存期（GALAXY-1研究）

　　一项大型随机II期临床研究GALAXY-1发现与标准的二线多西他赛单药治疗相比，一种新型热休克蛋白（Hsp）90抑制剂ganetespib，与多西他赛联合用于初始治疗后疾病进展的晚期肺腺癌患者的二线（挽救性）治疗时，可延长患者总生存期。如果目前正在进行的一项III期临床试验能够证实上述结果，这将是十年来首款能改善患者预后的治疗药物。　　Hsp90属于一类被称为“分子伴侣”的蛋白。分子伴侣能帮助

JTD：NSCLC患者术后对多西他赛/卡铂辅助治疗耐受良好

对于接受了手术治疗的非小细胞肺癌（NSCLC）患者而言，其在术后应用多西他赛/卡铂化疗方案时的安全性和耐受性，目前还不清楚，为了加深对这一问题的了解，来自广州呼吸疾病研究所，广州医科大学第一附属医院的何建行院长及其团队进行了一项研究，研究结果发表于2013年10月出版的《胸部疾病杂志》（J Thorac Dis）上。结果显示：多西他赛和卡铂作为NSCLC术后患者的辅助治疗，具有良好的耐受性。同时，

JCO：zibotentan联合多西他赛不能改善转移性去势抵抗前列腺癌患者生存

ENTHUSE (内皮素A的应用) 研究项目的组成部分之一是内皮素A受体拮抗剂zibotentan药效与安全性(ZD4054)研究(NCT00617669)，该部分研究针对转移性去势抵抗前列腺癌(CRPC)患者，旨在对zibotentan联合多西他赛的治疗方案进行考察。在2013年4月8日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncolgoy)上，法国巴黎第十一大学

JCO：贝伐单抗联合多西他赛及曲妥珠单抗不能改善乳腺癌患者无进展生存率

在2013年4月8日在线出版的《临床肿瘤学杂志》(Journal of Clinical Oncology)上，意大利米兰San Raffaele医院的Luca Gianni发文对AVEREL临床III期试验的结果进行了报告，AVEREL [阿瓦斯汀(贝伐单抗)联合赫赛汀(曲妥珠单抗)/多西他赛治疗HER2呈阳性的转移性乳腺癌患者]临床试验主要针对人表皮生长因子受体2(HER2)呈阳性的局部复发性

ASCO 2013：中山大学张力教授确定亚洲NSCLC人群进行多西他赛维持治疗更佳剂量

背景： 根据相关报告，多西他赛(75 mg/m 2 )可用于西方晚期NSCLC患者群的一线和维持治疗。而目前亚洲患者在进行多西他赛治疗时，用药剂量却有所不同(60 mg/m 2 )。这种差异或可通过不同种族间在紫杉醇代谢方面的药物遗传变异予以解释。TFINE研究对多西他赛维持治疗的药效、安全性以及耐受性进行了评价，同时本研究也试图确定亚组人群在进行多西他赛治疗时的最佳剂量。 方法：本研究入选人群